Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) shot up 3% during mid-day trading on Monday . The stock traded as high as $7.38 and last traded at $7.30, with a volume of 788,711 shares. The stock had previously closed at $7.09.

Several research firms have issued reports on KERX. Cowen and Company restated a “hold” rating on shares of Keryx Biopharmaceuticals in a report on Saturday, April 30th. Morgan Stanley reiterated a “hold” rating on shares of Keryx Biopharmaceuticals in a report on Saturday, April 30th. FBR & Co reiterated a “buy” rating and issued a $13.00 price target on shares of Keryx Biopharmaceuticals in a report on Friday, April 29th. Maxim Group reiterated a “buy” rating and issued a $9.00 price target (up from $7.00) on shares of Keryx Biopharmaceuticals in a report on Friday, July 8th. Finally, Zacks Investment Research upgraded Keryx Biopharmaceuticals from a “hold” rating to a “buy” rating and set a $8.00 price target for the company in a report on Wednesday, July 13th. Three equities research analysts have rated the stock with a sell rating, four have given a hold rating and eight have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of $8.84.

The stock has a 50-day moving average price of $6.43 and a 200 day moving average price of $4.99. The firm’s market capitalization is $771.43 million.

Keryx Biopharmaceuticals (NASDAQ:KERX) last announced its earnings results on Thursday, April 28th. The biopharmaceutical company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of ($0.26) by $0.13. The company earned $6.80 million during the quarter, compared to analysts’ expectations of $6.63 million. During the same period last year, the firm posted ($0.28) EPS. The firm’s revenue for the quarter was up 466.7% compared to the same quarter last year. Equities research analysts expect that Keryx Biopharmaceuticals Inc. will post ($0.98) earnings per share for the current fiscal year.

A hedge fund recently bought a new stake in Keryx Biopharmaceuticals stock. Royce & Associates LLC purchased a new stake in shares of Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 341,725 shares of the biopharmaceutical company’s stock, valued at approximately $1,726,000. Royce & Associates LLC owned 0.32% of Keryx Biopharmaceuticals as of its most recent SEC filing.

Keryx Biopharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development of products for the treatment of renal diseases. The Company’s product Auryxia (ferric citrate), also known as Riona in Japan and Fexeric in Europe, is an oral, absorbable iron-based compound, which is indicated for the control of serum phosphorus levels in patients with chronic kidney disease (CKD), on dialysis.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.